Literature DB >> 32250239

Point of care testing of Influenza A/B and RSV in an adult respiratory assessment unit is associated with improvement in isolation practices and reduction in hospital length of stay.

Louise Berry1, Louise Lansbury2, Lydia Gale1, Ann Marie Carroll1, Wei Shen Lim3.   

Abstract

Introduction. Every winter seasonal influenza and other viral respiratory infections increase pressure on the health services and are associated with nosocomial infection and morbidity.Aim. To compare provision of point-of-care (POC) testing with laboratory-based testing for influenza and RSV detection on an adult respiratory assessment unit to assess the impact on isolation practices and length of stay (LOS).Methodology. Prospective interrupted 'on-off' study in adults admitted to the respiratory unit between December 2018 and April 2019 with a suspected respiratory tract infection. Nasopharyngeal samples were tested using either the GeneXpert rapid POC test for influenza and RSV (on-period), or were sent to the laboratory for multiplex PCR testing against a panel of 12 respiratory viruses (off-period). Outcome measures were time to patient isolation for infection control, LOS and turnaround time from admission to test results.Results. Of 1145 patients evaluated, 755 were tested with POC and 390 with laboratory multiplex; a respiratory virus was identified in 164 (21.7 %) and 138 (35.4 %) patients respectively. A positive POC test was associated with a shorter time to isolation (mean difference 16.9 h, P<0.001), shorter LOS (mean difference 15.5 h, P=0.05,) and shorter turnaround time (mean difference 28.3 h, P<0.001), compared to laboratory testing.Conclusion. Use of GeneXpert POC testing for Flu/RSV is associated with rapid reporting of results with significant improvements in isolation practices and reductions in LOS.

Entities:  

Keywords:  influenza; isolation; length of stay; point-of-care test; respiratory syncytial virus; respiratory tract infections

Mesh:

Year:  2020        PMID: 32250239     DOI: 10.1099/jmm.0.001187

Source DB:  PubMed          Journal:  J Med Microbiol        ISSN: 0022-2615            Impact factor:   2.472


  3 in total

1.  Clinical evaluation of the GeneXpert® Xpert® Xpress SARS-CoV-2/Flu/RSV combination test.

Authors:  Grant Johnson; Arek Zubrzycki; Michele Henry; Charlene Ranadheera; Cindi Corbett; Adrienne F A Meyers; Paul A Sandstrom; Michael G Becker
Journal:  J Clin Virol Plus       Date:  2021-04-12

2.  Added value of rapid respiratory syndromic testing at point of care versus central laboratory testing: a controlled clinical trial.

Authors:  Donia Bouzid; Enrique Casalino; Jimmy Mullaert; Odile Laurent; Xavier Duval; François Xavier Lescure; Nathan Peiffer Smadja; Sarah Tubiana; Laurence Armand Lefèvre; Diane Descamps; Nadhira Fidouh; Christophe Choquet; Jean-Christophe Lucet; Benoit Visseaux
Journal:  J Antimicrob Chemother       Date:  2021-09-23       Impact factor: 5.790

3.  Risk factors and medical resource utilization in US adults hospitalized with influenza or respiratory syncytial virus in the Hospitalized Acute Respiratory Tract Infection study.

Authors:  Jessica Hartnett; Prina Donga; Gabriela Ispas; Yannick Vandendijck; David Anderson; Stacey House; Selim Suner
Journal:  Influenza Other Respir Viruses       Date:  2022-04-26       Impact factor: 5.606

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.